Table 1.
Detailed information of the studies and datasets used for Mendelian randomization analyzes.
| Traits | Population | Sample size (cases/controls) | Data source | PMID |
|---|---|---|---|---|
| Exposure | ||||
| COVID-19 susceptibility | Europeans | 112,612/2,474,079 | COVID-19 HGI | 32,404,885 |
| COVID-19 hospitalization | Europeans | 24,274/2,061,529 | COVID-19 HGI | 32,404,885 |
| COVID-19 severity | Europeans | 8,779/1,001,875 | COVID-19 HGI | 32,404,885 |
| Outcome | ||||
| ASD | Europeans | 18,382/27,969 | PGC | 33,686,288 |
| MDD | Europeans | 135,458/344,901 | PGC | 30,718,901 |
| BID | Europeans | 20,352/31,358 | PGC | 34,002,096 |
| SCZ | Europeans | 33,640/43,456 | PGC | 35,396,580 |
| Anxiety disorder | Europeans | 25,453/58,113 | UKB | 31,748,690 |
ASD, autism spectrum disorder; MDD, major depressive disorder; BID, bipolar disorder; SCZ, Schizophrenia; UKB, the UK Biobank; PGC, the Psychiatric Genomics Consortium; COVID-19 HGI, COVID-19 Host Genetics Initiative.